IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy

Interleukin (IL)-23, an IL-12 cytokine family member, is a hierarchically dominant regulatory cytokine in a cluster of immune-mediated inflammatory diseases (IMIDs), including psoriasis, psoriatic arthritis, and inflammatory bowel disease. We review IL-23 biology, IL-23 signaling in IMIDs, and the e...

Full description

Bibliographic Details
Main Authors:	James G. Krueger, Kilian Eyerich, Vijay K. Kuchroo, Christopher T. Ritchlin, Maria T. Abreu, M. Merle Elloso, Anne Fourie, Steven Fakharzadeh, Jonathan P. Sherlock, Ya-Wen Yang, Daniel J. Cua, Iain B. McInnes
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-04-01
Series:	Frontiers in Immunology
Subjects:	IL-23 cytokine immune-mediated inflammatory diseases psoriasis psoriatic arthritis inflammatory bowel disease
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1331217/full

Similar Items

IL-23 past, present, and future: a roadmap to advancing IL-23 science and therapy
by: Krueger, JG, et al.
Published: (2024)

Guselkumab binding to CD64+ IL-23–producing myeloid cells enhances potency for neutralizing IL-23 signaling
by: Kacey L. Sachen, et al.
Published: (2025-03-01)

Role of the IL-23/IL-17 Pathway in Rheumatic Diseases: An Overview
by: Claudia Schinocca, et al.
Published: (2021-02-01)

Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities
by: Gloria Pastor-Fernández, et al.
Published: (2020-09-01)

Editorial: Role of the IL-23/IL-17 Pathway in Chronic Immune-Mediated Inflammatory Diseases: Mechanisms and Targeted Therapies
by: Elisabetta Bianchi, et al.
Published: (2021-09-01)

The role of interleukin (IL)-23 in regulating pain in arthritis
by: Kevin M.-C. Lee, et al.
Published: (2022-04-01)

Why Inhibition of IL-23 Lacked Efficacy in Ankylosing Spondylitis
by: Dennis McGonagle, et al.
Published: (2021-03-01)

All are Equal, Some are More Equal: Targeting IL 12 and 23 in IBD – A Clinical Perspective
by: Jefremow A, et al.
Published: (2020-11-01)

Neolithic introgression of IL23R-related protection against chronic inflammatory bowel diseases in modern EuropeansResearch in context
by: Ben Krause-Kyora, et al.
Published: (2025-03-01)

The IL-17/IL-23 Axis and Its Genetic Contribution to Psoriatic Arthritis
by: Matteo Vecellio, et al.
Published: (2021-01-01)

The protective effect of IL‐12/23 neutralizing antibody in sarcopenia associated with dextran sulfate sodium‐induced experimental colitis
by: Youn‐Kwan Jung, et al.
Published: (2023-04-01)

IL-23/IL-17 INHIBITORS IN IMMUNOINFLAMMATORY RHEUMATIC DISEASES: NEW HORIZONS
by: E. L. Nasonov, et al.
Published: (2019-09-01)

Anti-IL23/12 agents and JAK inhibitors for inflammatory bowel disease
by: Zhezhe Tian, et al.
Published: (2024-07-01)

IL-23 Inhibitors to treat psoriatic arthritis: A systematic review & meta-analysis of randomized controlled trials
by: Ahmed Safi Vahidy, et al.
Published: (2023-12-01)

The Association Study of IL-23R Polymorphisms With Cerebral Palsy in Chinese Population
by: Yangong Wang, et al.
Published: (2020-11-01)

The regulatory mechanism and potential application of IL-23 in autoimmune diseases
by: De-Kai Xiong, et al.
Published: (2022-09-01)

The Role of the IL-23/IL-17 Axis in Disease Initiation in Spondyloarthritis: Lessons Learned From Animal Models
by: Mohamed Mandour, et al.
Published: (2021-06-01)

Remission, low disease activity and improvement of pain and function in psoriatic arthritis patients treated with IL-12/23 and IL-17 inhibitors. A multicenter prospective study
by: F.M. Perrotta, et al.
Published: (2020-04-01)

Efficacy of IL-23 inhibitors and IL-12/23 inhibitors in the induction treatment of Crohn’s disease: A meta-analysis based on randomized controlled trials
by: Boyang Gao, et al.
Published: (2024-01-01)

IL-23 Promotes Myocardial I/R Injury by Increasing the Inflammatory Responses and Oxidative Stress Reactions
by: Xiaorong Hu, et al.
Published: (2016-05-01)

Drug survival of IL-12/23, IL-17 and IL-23 inhibitors for moderate-to-severe plaque psoriasis: a retrospective multicenter real-world experience on 5932 treatment courses – IL PSO (Italian landscape psoriasis)
by: Luigi Gargiulo, et al.
Published: (2024-01-01)

Association between 23 drugs and inflammatory bowel disease: a two-sample Mendelian randomization study
by: Lei He, et al.
Published: (2024-05-01)

IL-17A, IL-17F and IL-23 in patients with rheumatoid arthritis
by: Natalia A. Lapkina, et al.
Published: (2024-09-01)

Mini Review: New Treatments in Psoriatic Arthritis. Focus on the IL-23/17 Axis
by: Lazaros I. Sakkas, et al.
Published: (2019-08-01)

From Bed to Bench and Back: TNF-α, IL-23/IL-17A, and JAK-Dependent Inflammation in the Pathogenesis of Psoriatic Synovitis
by: Ettore Silvagni, et al.
Published: (2021-06-01)

No Significant Effects of IL-23 on Initiating and Perpetuating the Axial Spondyloarthritis: The Reasons for the Failure of IL-23 Inhibitors
by: Hua Zhang, et al.
Published: (2022-02-01)

Significance of Interleukin (IL)-4 and IL-13 in Inflammatory Arthritis
by: Milena Iwaszko, et al.
Published: (2021-11-01)

Role of the IL23/IL17 Pathway in Crohn’s Disease
by: Heike Schmitt, et al.
Published: (2021-03-01)

Prospects for the use of monoclonal antibodies to interleukin 23 Gusеlkumab in psoriatic arthritis: New data
by: E. L. Nasonov, et al.
Published: (2022-03-01)

p19-targeted ABD-derived protein variants inhibit IL-23 binding and exert suppressive control over IL-23-stimulated expansion of primary human IL-17+ T-cells
by: Lucie Křížová, et al.
Published: (2017-02-01)

IL-12 and IL-23—Close Relatives with Structural Homologies but Distinct Immunological Functions
by: Doreen M. Floss, et al.
Published: (2020-09-01)

The mode of action of IL-23 in experimental inflammatory arthritic pain and disease
by: Kevin M.-C. Lee, et al.
Published: (2024-08-01)

Novel bispecific nanobody mitigates experimental intestinal inflammation in mice by targeting TNF‐α and IL‐23p19 bioactivities
by: Jiewen Wang, et al.
Published: (2024-03-01)

A non-clinical comparative study of IL-23 antibodies in psoriasis
by: Li Zhou, et al.
Published: (2021-01-01)

Correlation between Human Boca virus and IL-23in some Iraqi patients with ischemic heart disease
by: Rafal Hussein Alshate, et al.
Published: (2024-04-01)

Il Fibroblast Growth Factor-23 (FGF-23)
by: D. Rendina, et al.
Published: (2018-01-01)

IL-23 Gene and Protein Expression in Childhood Asthma
by: Soheila Alyasin, et al.
Published: (2017-03-01)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018-11-01)

Crohn’s disease exacerbated by IL-17 inhibitors in patients with psoriasis: a case report
by: Jingyi Ju, et al.
Published: (2020-10-01)

Association of IL23R Variants With Crohn’s Disease in Korean Children
by: Jeana Hong, et al.
Published: (2019-11-01)